Teladoc Health, Inc. $TDOC Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. trimmed its position in Teladoc Health, Inc. (NYSE:TDOC) by 65.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 210,926 shares of the health services provider’s stock after selling 391,709 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.12% of Teladoc Health worth $1,630,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bridgeway Capital Management LLC bought a new position in Teladoc Health during the second quarter worth $8,729,000. Empowered Funds LLC bought a new position in shares of Teladoc Health in the 2nd quarter worth about $5,040,000. Allianz Asset Management GmbH boosted its holdings in shares of Teladoc Health by 2,605.0% in the 2nd quarter. Allianz Asset Management GmbH now owns 559,933 shares of the health services provider’s stock valued at $4,877,000 after buying an additional 539,233 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Teladoc Health during the 2nd quarter valued at about $2,722,000. Finally, Brevan Howard Capital Management LP grew its position in shares of Teladoc Health by 1,540.1% during the 2nd quarter. Brevan Howard Capital Management LP now owns 332,299 shares of the health services provider’s stock valued at $2,894,000 after buying an additional 312,038 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Trading Down 2.0%

Shares of TDOC stock opened at $7.46 on Monday. Teladoc Health, Inc. has a 1 year low of $6.35 and a 1 year high of $15.21. The firm has a market capitalization of $1.32 billion, a PE ratio of -5.82 and a beta of 2.04. The stock has a fifty day moving average of $7.38 and a two-hundred day moving average of $7.81. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. The business had revenue of $626.44 million for the quarter, compared to analysts’ expectations of $625.66 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. The company’s revenue was down 2.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.19) earnings per share. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. As a group, research analysts expect that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on TDOC shares. Barclays initiated coverage on Teladoc Health in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 target price for the company. BMO Capital Markets assumed coverage on Teladoc Health in a research report on Thursday, November 13th. They set a “market perform” rating and a $8.00 price objective for the company. Citigroup dropped their target price on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Friday. Bank of America cut their target price on Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 25th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.50.

Insider Activity at Teladoc Health

In other news, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This represents a 7.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Adam C. Vandervoort sold 5,720 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the transaction, the insider owned 80,732 shares of the company’s stock, valued at $604,682.68. This trade represents a 6.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,288 shares of company stock valued at $251,684 over the last quarter. Corporate insiders own 0.58% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.